Background and Aims: Studies evaluating the impact of integrated models of care [IMC] for inflammatory bowel disease [IBD] on disease-related outcomes are needed. We compared the risk of IBD-related outcomes and prescription medication claims between patients exposed and nonexposed to an IMC. Methods: A retrospective population-based matched cohort study was conducted between 2009 and 2015, using administrative health data of Saskatchewan, Canada. Patients aged 18+ years with a diagnosis of IBD were identified with a validated administrative definition. Cases were classified as exposed and non-exposed to the IMC for IBD and matched based on propensity scores and disease duration. IBD-related hospitalisations, surgeries, prescription medication claims, and corticosteroid dependency [CsDep] were measured. Cox and logistic regression models evaluated differences between the groups, estimating hazard [HRs] and odds [ORs] ratios with corresponding confidence intervals [CIs]. Results: In total, 2312 matched patients were included; 24.3% were exposed individuals. Compared with non-exposed, exposed patients had a lower risk Conclusions: The observed differences in disease-related outcomes and use of steroid-sparing maintenance therapies between exposed and non-exposed individuals support the concept that enhanced quality of care can be achieved within IMC for IBD.
Introduction
The fragmented provision of health services is a structural problem of health care systems which negatively affects access to health care, health care quality, health outcomes, health equity, appropriate use of technologies, satisfaction of patients and families, and health care costs. 1, 2 Integrated models of care [IMC] have been implemented worldwide as a response to the segregated delivery of health care, 2, 3 aiming for more comprehensive health care systems. 2 These types of innovative models bring together 'inputs, delivery, management and organization of services related to diagnosis, treatment, care, rehabilitation and health promotion to improve access, quality, user satisfaction and efficiency'. 4 From a system-and patient-centred view, IMC are efforts of health systems to be comprehensive through the implementation of strategies to fund, administrate, and organise service delivery, promoting connectivity, alignment, and collaboration. 2 Different examples of IMC have been implemented with a variety of designs and foci. [5] [6] [7] [8] Among IMC for chronic diseases, numerous IMC have been developed for patients living with inflammatory bowel disease [IBD] , including Crohn's disease [CD] and ulcerative colitis [UC]. 5 Inflammatory bowel disease is an incurable chronic inflammatory condition of the gastrointestinal tract that requires lifelong interactions with the health care system. 5, 9 Poorly controlled IBD is associated with reduced quality of life, psychological distress, and complications such as intestinal obstruction, perforation, infection, fistulas, and malignancy. 10 Moreover, due to the complexity and chronicity of this condition, IBD impacts on patients, families, and health care systems. [11] [12] [13] Patients and families living with IBD report a negative impact of the disease on their interpersonal relationships and leisure activities. 11 A considerable amount of health care resources are required for disease management, with substantial direct and indirect costs. 13 IMC for IBD have been implemented 5 as a response to the growing prevalence and incidence of IBD, 12 the disease complexity, and the importance of an inter-professional approach to manage and support the biopsychosocial needs of patients living with IBD. 5, 14 Some of the common features of IMC for IBD include patientcentred care, mechanisms for active follow-up, inter-professional teamwork, a comprehensive biopsychosocial approach, a focus on education and prevention, and a central role for IBD nurses in the provision and coordination of care. 5 IMC for IBD have the potential to improve quality of care, 15 provide active follow-up, introduce early steroid-sparing maintenance therapies, screen for diseaserelated comorbidities, and reduce corticosteroid exposure, as well as disease-related hospitalisations and surgeries. 16 However, few studies have evaluated the impact of IMC for IBD on health resource utilisation and patient outcomes. Furthermore, there is a current need of evidence about the impact of early use of biologics and frequent follow-up strategies on the progression of the disease; 17 these are strategies commonly seen among IMC for IBD. Our objective was to compare IBD-related hospitalisations and surgical treatments, prescription medication claims, and corticosteroid dependency [CsDep] between IMC exposed and non-exposed patients.
Materials and Methods

Study design and data sources
A retrospective population-based matched cohort study was conducted using provincial health administrative databases from the Canadian province of Saskatchewan. The province has an ethnically diverse population of one million 18 and comprehensive administrative health databases that capture all insured health services in its universal and single-payer structure. 19 Saskatchewan is estimated to have 498.1/100 000 prevalent IBD cases and 23.9/100 000 new cases annually. 20 The University of Saskatchewan Multidisciplinary IBD Clinic [MDIBDC] was initiated in January 2009. The MDIBDC implemented a coordinated patient-centred model of care provided by IBD fellowship-trained gastroenterologists, nurse practitioners, nurse clinicians, a clinical health psychologist, and a clinical dietitian with expertise in gastrointestinal nutrition. The main goal of the MDIBDC was to assure quality and a continuum of health care for patients with IBD in the province.
Comprehensive health administrative databases, including hospital discharge abstracts, physician billing claims, prescription medication dispensation records, and population registry files from the Saskatchewan Ministry of Health, were used to conduct this study. Diagnoses in hospital discharge abstracts are coded using the 23 Individuals had to be at least 18 years of age at the time of their first health care contact with diagnosis of IBD. Cases were classified as CD or UC considering the most prevalent diagnosis across health care contacts.
Individuals who met the IBD case definition between January 1, 2009 and March 31, 2015 were classified in the exposed or nonexposed groups using the selection criteria presented in Table 1 . These dates were defined based on the inception of the MDIBDC and end of the study period. The billing numbers of physicians were used to identify patients who had baseline and follow-up visits at the MDIBDC. 
Study outcomes and covariates
Statistical analysis
Propensity score matching
Propensity score [PS] matching 25, 26 was used to balance the confounding effects of health care use variables and comorbidity at the baseline visit, obtaining matched sets of exposed and non-exposed patients. The PSs were estimated using a logistic regression model predicting the likelihood of being assigned to the exposed group. Comorbidity and IBD-related and non-IBD-related health care utilisation indicators were measured 1 year before the baseline visit and included in the model [ Table 3 ]. Given that a previous population-based study demonstrated that disease course of IBD could be predicted using health care utilisation measures from administrative databases, 27, 28 our model considered physician visits with a diagnosis of IBD, prescriptions for IBD, CsDep, IBD-related hospitalisations, and IBD-related surgeries in a 1-year period before the baseline visit as proxy measures for disease severity. Comorbidity was measured with the Charlson-Deyo comorbidity index, 29, 30 using diagnosis codes in hospital and physician data.
Exposed and non-exposed individuals were matched on PSs and duration of disease [measured in years from the first IBD diagnosis to the baseline visit] with a caliper of 0.05 and 0.50, respectively, and using nearest-neighbourhood matching. 26 We used 1:5 matching to include multiple unexposed individuals per each exposed individual. Non-matched exposed individuals were excluded from the analyses.
Association between exposure and outcomes
Multivariable Cox proportional hazards models 31 were used to estimate hazard ratios [HRs] and 95% confidence intervals [95% CIs] for the association between IMC exposure and IBD-related hospitalisations, surgical treatments, and prescriptions of biologics, IM, and 5-ASA. Proportional hazards models can account for the varying length of the observation time for cohort members. Thus, the length of follow-up was the offset term for each model and was measured in person-months of health coverage from the baseline visit, and terminated either by the presence of the event or censoring. To test the association between CsDep and exposure to the MDIBDC, a conditional logistic regression model was used to estimate odds ratios [OR] and 95% CIs for CsDep. The logistic regression models included individuals who had 18 months of follow-up after the baseline visit, comprising the 1-year washout period and six months to measure CsDep.
All models included type of IBD, sex, age, and location of residence as covariates. Furthermore, after additional matching within CD and UC groups, stratified models by type of IBD were run considering sex, age, and location of residence as covariates. A sensitivity analysis was completed by running all the models without matching but including the PSs and duration of disease as additional covariates. Statistical analyses were conducted in SAS version 9. 
Results
From the 7263 adult individuals in the Saskatchewan IBD cohort, 3913 with the diagnosis of IBD met the exposed [n = 631] and nonexposed [n = 3282] criteria between January 1, 2009 and March 31, 2015. This group was eligible for inclusion in the analysis, calculating their disease duration in years and PSs based on health care use patterns a year before the baseline. After matching, 2312 individuals with the diagnosis of IBD were included in the study, with 562 and 1750 in the exposed and non-exposed groups, respectively [ Figure 1 ]. Thus, 1601 cases were excluded either because exposed individuals did not have a match in the exposed group [ 69 cases] or because there were more than five non-exposed cases per one exposed individual [1532 cases]. Among the 2312 individuals included in the study [ Among the outcomes of interest, dissimilar distributions were observed between exposed and non-exposed groups [ Table 5 ]. Higher proportions of non-exposed individuals had an IBD-related hospitalisation, surgery for IBD, and CsDep than exposed individuals. Non-exposed individuals had more 5-ASA prescriptions in comparison with exposed individuals, but lower numbers of IM and biologics prescriptions.
The multivariable Cox proportional hazard models showed that the risk of surgeries for IBD in the exposed group was lower than in the non-exposed group [HR = 0.72, 95% CI 0.57-0.91]. In contrast, there were no significant differences in the risk of hospitalisations [HR = 0.92, 95% CI 0.79- 
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Propensity score a and disease duration b matching non-exposed group. Additionally, the exposed group had an HR of 0.79 [95% CI 0.68-0.92] for 5-ASA prescriptions; in other words, non-exposed individuals had a risk of 5-ASA prescription claims 1.27 times higher than the exposed ones [ Table 6 ].
The stratified analysis by type of disease identified additional differences between the groups, specifically among individuals diagnosed with UC. The risk of IBD-related hospitalisations in the exposed UC group was lower than in the non-exposed group [HR = 0.71, 95% CI 0.53-0.94]. Similarly, the odds of CsDep among individuals diagnosed with UC were lower in the exposed group [0.39, 95% CI 0.15-0.98] than in the non-exposed group [ Table 6 ]. The sensitivity analysis included 3913 individuals with IBD, 631 exposed and 3282 non-exposed. This analysis demonstrated similar estimates, with narrower CIs, than those presented above. 
Discussion
This is the first population-based study in the literature demonstrating the impact of an IMC on IBD-related outcomes. Individuals receiving care at an IMC for IBD had a lower risk of surgery for IBD and earlier introduction of IM and biologic medications, compared with those managed outside this model. Moreover, we identified a lower risk of IBD-related hospitalisation and odds of CsDep among exposed UC patients in comparison with the non-exposed ones.
Although focusing on a different patient population, a previous retrospective cohort study evaluating the impact of an inpatient IBD care model did not identify differences between the study and control periods regarding surgeries 90 days post-discharge, but reported more early surgeries facilitated by the model. 32 The same study identified higher odds of using high-dose biologic therapy in the study period than the control period, 32 a finding supporting our results. Our study also identified a lower risk of disease-related hospitalisations among patients diagnosed with UC. The potential reduction of IBD-related hospitalisations agrees with the lower number of hospitalisations after the implementation of an IBD clinic, identified by McBride. 33 Their evaluation was done before and after the programme implementation; however, the study did not consider a control group or confounding variables. 33 Another study demonstrated an improved access to diagnostic tests [regular blood testing and colonoscopies] at IBD specialist clinics in comparison with general gastroenterology clinics; however, long-term outcomes were not reported. 34 The three studies described above were based on chart reviews [32] [33] [34] and were subject to selection bias. In contrast, our approach included a non-exposed comparison group and applied an analysis that controlled the results for health care use variables, disease duration, comorbidity, and sociodemographic factors. The differences observed in our study between IMC-exposed and IMC non-exposed individuals in the use of 5-ASA, IM, and biologic prescriptions, along with lower odds of CsDep among individuals with UC, suggest that patients followed within this care model may be receiving improved quality of care relative to a non-IMC model. This difference is a relevant finding, given that recent evidence pertaining to IBD pharmacotherapy supports early intervention with biologic and steroid-sparing therapy 17, 35 and that timely access to these therapies for the right patients is a recognised process indicator of IBD quality of care. 16 Furthermore, it is important to highlight that non-exposed individuals had a higher risk of 5-ASA prescription claims than exposed individualss, a difference confirmed only among individuals with CD. In other words, there was no evidence that the use of 5-ASA differs among UC patients, but significant differences in the medical management of CD disease could be assumed between the integrated and non-integrated models of care.
Our study and previous works support the value of IMC to improve the quality of care provided to patients with IBD. [32] [33] [34] This benefit could be attributed to a substantial role of IBD nurses, comprehensive biopsychosocial assessment of patients, disease education, and the presence of a mechanism for active follow-up. 5 Evidence suggests that IBD nurse interventions affect patient outcomes. 36, 37 Nurses dedicated to IBD care are important professionals of IMC for IBD, who contribute to quality of care enhancement, greater access to care, provision of holistic care approaches which address biopsychosocial aspects, improved continuity of care, and facilitation of inter-professional work. 37 Active follow-up is another characteristic that could explain better outcomes within IMC for IBD, by providing an early prescription to maintain patients in remission. Gastroenterologists trained in IBD play a substantial role in providing improved quality of care within IMC for IBD, as leaders of these models. 5 Moreover, telemedicine and nurse-led telephone follow-up are innovative and promising initiatives to ensure periodical follow-up of patients with IBD. 38, 39 These are attributes present at the Saskatchewan IMC for IBD.
Our results also are aligned with previous studies demonstrating a positive impact of IMC on health of individuals living with chronic and complex conditions. [5] [6] [7] [8] [40] [41] [42] [43] [44] [45] Some of these studies provide strong evidence about the impact of IMC through randomised trials. 40, 43, 44 For example, individuals exposed to an IMC for psychiatric illness were more likely to have more follow-up visits, receive recommended preventive health activities, and have a better health status than those in the control group. 44 In another randomised trial, patients with hepatitis C exposed to an IMC had a greater proportion of antiviral therapy and a sustained virological response compared with the control group. 43 Also, exposure to an IMC for elderly patients was associated with lower numbers of hospitalisations and nursing home admissions. 40 Our study has some limitations due to its design and data source. First, this is a retrospective observational study subject to confounding; however, we addressed this issue using PSs that accounted for IBD-related and non-IBD related health care use patterns and comorbidity preceding the baseline visit. The use of matching based on PSs, as well as disease duration, should have addressed the issue of residual confounding. There was a small difference in the mean PSs of the groups after matching, due to the caliper used; notwithstanding, we tested the models including disease duration and PSs as covariables, observing a similar direction and strength of the associations. Another limitation of our study is the absence of the ability to capture disease severity in the administrative databases. This is a relevant covariable when evaluating disease-related outcomes. To overcome this limitation, PSs considered previous IBD-related medication claims, hospitalisations, surgeries, and number of outpatient visits with a diagnosis of IBD. This approach has been suggested as a valid proxy to measure severity of IBD. 27 Furthermore, we acknowledge that the limited number of individuals in the exposed group could affect the ability to detect significant differences between exposed and non-exposed groups, as was likely the case with overall estimates of IBD hospitalisations and CsDep. It is important to highlight that IMC for IBD could also improve non-IBD related hospitalisations and reduce complications related to the use of IBD therapies. However, the limited sample size in our cohort did not allow further comparisons of non-IBD related health care use between the groups.
We also acknowledge the limitation in assessing corticosteroid use by prescription medication claims data, especially in our data which did not have details to estimate the end date of the medications. We evaluated corticosteroid exposure in multiple ways, and selected the approach that identified cases requiring multiple steroid courses within a short period of time [two or more prescriptions of oral corticosteroids within 6 months]. Depending on data availability, further studies could consider annual cumulative intake of corticosteroids or use of oral corticosteroids for more than 3 months.
Nonetheless, the presented study demonstrates the promising potential of the use of administrative data to evaluate innovative models of care. Our retrospective study design could be replicable in settings where a universal health care system, single-payer scheme, and comprehensive databases of health services are available. Our methodological approach could be used to develop multicentre studies allowing further evaluation of IMC for IBD. Given the nature of administrative health databases, our data did not capture patientreported outcomes such as quality of life, self-reported disease control, patient satisfaction, etc. Further prospective studies measuring and comparing patient-reported outcomes, as well as health care use patterns and clinical outcomes [IBD-related and non-IBD related surgeries, hospitalisations, emergency visits, steroid use, etc], could provide a comprehensive evaluation of the impact of IMC on patients living with IBD. Assessing patient perceptions regarding IMC could also help in understanding which components of the IMC patients find most valuable. Also, future research is required to evaluate cost-efficacy of IMC.
In conclusion, we demonstrated that exposure to an IMC for IBD is associated with improved quality of care and greater access to IBD care and medical therapeutics. We identified differences between exposed and non-exposed individuals in the risk of adverse disease-related outcomes and the use of steroid-sparing maintenance therapies. This study provides a framework to promote and justify the implementation and maintenance of IMC for IBD management. These IMC have the capacity to deliver equitable, timely, and high quality care for patients living with IBD, to impact on the health of individuals, and to make effective use of health care resources.
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